FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress | Special Issues

Infigratinib Active in Intrahepatic Cholangiocarcinoma

December 19, 2018

The selective pan-FGFR kinase inhibitor infigratinib showed meaningful antitumor activity and a manageable safety profile in patients with previously treated intrahepatic cholangiocarcinoma who harbor FGFR2 fusions.

Pemigatinib Emerging as Potential Second-Line Treatment for Cholangiocarcinoma

December 19, 2018

The potent FGFR1-3 inhibitor pemigatinib showed preliminary efficacy and safety signals in the phase II FIGHT-202 trial (NCT02924376) of patients with previously treated advanced, metastatic or surgically unresectable cholangiocarcinoma.